

**TARGET ALS FOUNDATION, INC.**

**Financial Statements  
and Supplementary Information**

**Year Ended December 31, 2025**

**(With Independent Auditors' Report Thereon)**

**TARGET ALS FOUNDATION, INC.**  
**FINANCIAL STATEMENTS  
AND SUPPLEMENTARY INFORMATION**  
**Year Ended December 31, 2025**

	<u>Page</u>
INDEPENDENT AUDITORS' REPORT	1
FINANCIAL STATEMENTS:	
Statement of Financial Position (With Comparative Totals at December 31, 2024)	4
Statement of Activities (With Comparative Totals for the Year Ended December 31, 2024)	5
Statement of Functional Expenses (With Comparative Totals for the Year Ended December 31, 2024)	6
Statement of Cash Flows (With Comparative Totals for the Year Ended December 31, 2024)	7
Notes to the Financial Statements	8
SUPPLEMENTARY INFORMATION:	
Program Accomplishments (Unaudited)	17

## **INDEPENDENT AUDITORS' REPORT**

To the Board of Directors of  
Target ALS Foundation, Inc.:

### **Opinion**

We have audited the accompanying financial statements of Target ALS Foundation, Inc. (a not-for-profit organization) (the Foundation), which comprise the statement of financial position as of December 31, 2025, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Target ALS Foundation, Inc. as of December 31, 2025, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

### **Basis for Opinion**

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Responsibilities of Management for the Financial Statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

## **Auditors' Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

## **Report on Summarized Comparative Information**

We have previously audited the Foundation's 2024 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated May 5, 2025. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2024, is consistent, in all material respects and with the exception of certain reclassifications, with the audited financial statements from which it has been derived.

**Supplementary Information**

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The information on Supplemental Schedule I is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and is of a non-accounting nature. The information has not been subjected to the auditing procedures applied in the audit of the financial statements and, accordingly, we express no opinion on it.

*Kahn, Litwin, Renya & Co., Ltd.*

April 20, 2026

**TARGET ALS FOUNDATION, INC.**  
**STATEMENT OF FINANCIAL POSITION**  
**December 31, 2025**  
**(With Comparative Totals at December 31, 2024)**



	<b>2025</b>	<b>2024</b>
<b>Assets</b>		
Cash	\$ 7,957,798	\$ 10,489,781
Investments	83,184,297	68,783,323
Receivables:		
Grants, net	250,000	730,032
Pledges, net	45,444,945	48,581,875
Loan	-	250,000
Prepaid expenses	75,597	76,751
<b>Total Assets</b>	<b>\$ 136,912,637</b>	<b>\$ 128,911,762</b>
<b>Liabilities and Net Assets</b>		
Liabilities:		
Grants payable	\$ 1,828,304	\$ 4,318,332
Accounts payable and accrued expenses	25,316	33,343
<b>Total liabilities</b>	<b>1,853,620</b>	<b>4,351,675</b>
Net Assets:		
Without donor restrictions	97,650,305	81,346,621
With donor restrictions	37,408,712	43,213,466
<b>Total net assets</b>	<b>135,059,017</b>	<b>124,560,087</b>
<b>Total Liabilities and Net Assets</b>	<b>\$ 136,912,637</b>	<b>\$ 128,911,762</b>

**TARGET ALS FOUNDATION, INC.**  
**STATEMENT OF ACTIVITIES**  
**Year Ended December 31, 2025**  
**(With Comparative Totals for the Year Ended December 31, 2024)**



	<u>2025</u>	<u>2024</u>
Change in Net Assets Without Donor Restrictions:		
Revenue and Support:		
Contributions and grants	\$ 19,388,502	\$ 22,423,290
Investment earnings, net	6,210,346	3,097,236
Other income	6,322	1,502
Net assets released from restrictions	16,140,637	15,105,670
<b>Total revenue and support</b>	<u><b>41,745,807</b></u>	<u><b>40,627,698</b></u>
Expenses:		
Research	21,006,355	22,684,199
Management and general	2,677,001	3,368,111
Development	1,758,767	888,573
<b>Total expenses</b>	<u><b>25,442,123</b></u>	<u><b>26,940,883</b></u>
<b>Change in net assets without donor restrictions</b>	<u><b>16,303,684</b></u>	<u><b>13,686,815</b></u>
Change in Net Assets With Donor Restrictions:		
Contributions and grants	10,335,883	25,479,592
Net assets released from restrictions	(16,140,637)	(15,105,670)
<b>Change in net assets with donor restrictions</b>	<u><b>(5,804,754)</b></u>	<u><b>10,373,922</b></u>
<b>Change in Net Assets</b>	<b>10,498,930</b>	<b>24,060,737</b>
<b>Net Assets, beginning of year</b>	<u><b>124,560,087</b></u>	<u><b>100,499,350</b></u>
<b>Net Assets, end of year</b>	<u><u><b>\$ 135,059,017</b></u></u>	<u><u><b>\$ 124,560,087</b></u></u>

**TARGET ALS FOUNDATION, INC.**  
**STATEMENT OF FUNCTIONAL EXPENSES**  
**Year Ended December 31, 2025**  
**(With Comparative Totals for the Year Ended December 31, 2024)**

	<u>Research</u>	<u>Management and General</u>	<u>Development</u>	<u>2025 Total</u>	<u>2024 Total</u>
Research awards	\$ 18,765,868	\$ -	\$ -	\$ 18,765,868	\$ 21,639,451
Personnel and related:					
Salaries	710,549	1,542,978	661,217	2,914,744	2,380,556
Payroll taxes	48,967	104,303	47,573	200,843	155,837
Employee benefits	164,798	424,231	151,051	740,080	514,233
<b>Total personnel and related</b>	<b><u>924,314</u></b>	<b><u>2,071,512</u></b>	<b><u>859,841</u></b>	<b><u>3,855,667</u></b>	<b><u>3,050,626</u></b>
Other expenses:					
Advertising and promotion	-	-	802,482	802,482	158,606
Conferences, conventions and meetings	1,287,972	-	-	1,287,972	1,044,748
Meals	1,223	8,575	1,844	11,642	20,325
Office expenses	6,004	76,414	16,614	99,032	63,305
Professional services	-	318,630	63,487	382,117	738,632
Telephone and internet	-	143,162	-	143,162	82,159
Travel	20,974	58,708	14,499	94,181	143,031
<b>Total other expenses</b>	<b><u>1,316,173</u></b>	<b><u>605,489</u></b>	<b><u>898,926</u></b>	<b><u>2,820,588</u></b>	<b><u>2,250,806</u></b>
<b>Total Expenses</b>	<b><u>\$ 21,006,355</u></b>	<b><u>\$ 2,677,001</u></b>	<b><u>\$ 1,758,767</u></b>	<b><u>\$ 25,442,123</u></b>	<b><u>\$ 26,940,883</u></b>

See accompanying notes to the financial statements and independent auditors' report.

**TARGET ALS FOUNDATION, INC.**  
**STATEMENT OF CASH FLOWS**  
**Year Ended December 31, 2025**  
**(With Comparative Totals for the Year Ended December 31, 2024)**



	<u>2025</u>	<u>2024</u>
Cash Flows from Operating Activities:		
Change in net assets	\$ 10,498,930	\$ 24,060,737
Adjustments to reconcile change in net assets to net cash provided (used) by operating activities:		
Unrealized and realized gain on investments	(5,435,726)	(3,098,738)
Contributions of stock received	(6,315,624)	(3,797,358)
Discount on pledges and grants receivable	(2,801,815)	2,273,045
Changes in operating assets and liabilities:		
Grants receivable	642,997	1,500,000
Pledges receivable	5,775,780	(13,937,406)
Prepaid expenses	1,154	(28,516)
Grants payable	(2,490,028)	1,287,949
Accounts payable and accrued expenses	(8,027)	14,947
<b>Net cash provided (used) by operating activities</b>	<b><u>(132,359)</u></b>	<b><u>8,274,660</u></b>
Cash Flows from Investing Activities:		
Purchase of investments	(18,045,628)	(23,350,000)
Proceeds from sale of investments	15,396,004	-
Collection (issuance) of loan receivable	250,000	(250,000)
<b>Net cash used by investing activities</b>	<b><u>(2,399,624)</u></b>	<b><u>(23,600,000)</u></b>
<b>Net Decrease in Cash</b>	<b>(2,531,983)</b>	<b>(15,325,340)</b>
<b>Cash, beginning of year</b>	<b><u>10,489,781</u></b>	<b><u>25,815,121</u></b>
<b>Cash, end of year</b>	<b><u>\$ 7,957,798</u></b>	<b><u>\$ 10,489,781</u></b>
<b>Supplemental Cash Flow Information, noncash investing activities</b>		
Noncash contributions of investments	<b><u>\$ 6,315,624</u></b>	<b><u>\$ 3,797,358</u></b>

**TARGET ALS FOUNDATION, INC.**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**Year Ended December 31, 2025**

**1. Nature of Operations**

Target ALS Foundation, Inc. (the Foundation), a not-for-profit Delaware corporation operating in New York, New York, was incorporated on December 3, 2015 to promote, support, and further the funding of medical and scientific research to accelerate drug discovery and development for Amyotrophic Lateral Sclerosis (ALS). The Foundation pursues its mission by awarding grants to fund ALS - related research.

**2. Summary of Significant Accounting Policies**

This summary of significant accounting policies of the Foundation is presented to assist the reader in understanding the Foundation's financial statements. The financial statements and notes are representations of the Foundation's management, who is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

***Comparative Financial Information***

The accompanying financial statements include certain prior year summarized comparative information without accompanying note disclosures and certain functional expense information. Such information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the Foundation's financial statements and related notes to the financial statements for the year ended December 31, 2024, from which the summarized information was derived.

***Financial Statement Presentation***

The Foundation prepares its financial statements on the accrual basis of accounting and, in accordance with authoritative guidance, reports information regarding its financial position and activities according to two classes of net assets: net assets without donor restrictions, and net assets with donor restrictions.

***Net Assets without Donor Restrictions***

Net assets without donor restrictions are available for use at the discretion of the Board of Directors (the Board) and/or management for general operating purposes. From time to time, the Board may designate a portion of these net assets for specific purposes which make them unavailable for use at management's discretion.

***Net Assets with Donor Restrictions***

Net assets with donor restrictions consist of assets whose use is limited by donor-imposed time and/or purpose restrictions. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. The Foundation had no net assets to be maintained in perpetuity as of December 31, 2025.

**TARGET ALS FOUNDATION, INC.**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**Year Ended December 31, 2025**

Donor-restricted contributions are reported as increases in net assets with donor restrictions. When a restriction is satisfied, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the statement of activities.

***Investments and Fair Value Measurement***

The Foundation measures its investments at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market. Valuation techniques that are consistent with the market, income or cost approach, as specified by authoritative guidance, are used to measure fair value.

The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities the Foundation has the ability to access.

Level 2 inputs (other than quoted prices included within level 1) are observable for the asset or liability, either directly or indirectly.

Level 3 inputs are unobservable for the asset or liability and rely on management's own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and may include the Foundation's own data.

The Foundation reports investments at fair value on a recurring basis. The investments are classified as level 1 within the fair value hierarchy.

Level 1 investments owned by the Foundation and listed on a National Securities Exchange are valued at the last recorded sales price as of the financial statement reporting date, or, in the absence of recorded sales, at the last quoted bid price reported as of the financial statement reporting date.

Realized and unrealized gains and losses on investments are reported as changes in net assets without donor restrictions, unless gains and losses on investments are restricted by a donor's explicit stipulation or by a law that extends a donor's restriction.

Dividends and interest are recorded as received, which does not differ materially from the accrual basis. Purchases and sales of securities are recorded on the trade date.

**TARGET ALS FOUNDATION, INC.**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**Year Ended December 31, 2025**

***Receivables***

The Foundation carries its receivables at net realizable value. Pledges receivable consist of unconditional promises to give. Pledges and grants receivable that are expected to be collected within one year are recorded at net realizable value. Pledges and grants receivable expected to be collected after more than one year are recorded at the present value of the estimated future cash flows to be received. On a periodic basis, the Foundation evaluates its receivables and establishes an allowance for doubtful accounts, based on historical experience, current conditions, and reasonable and supportable forecasts.

The Foundation does not accrue interest on receivables. A receivable is considered past due if payment has not been received within stated terms. The Foundation will then exhaust all methods in-house to collect the receivable. Once all practical resources to collect the receivable have been utilized without success, the receivable is deemed uncollectible and charged against the allowance for doubtful accounts. At December 31, 2025, management determined that no allowance for doubtful accounts was necessary.

***Grants Payable***

Unconditional research grants are recognized in the financial statements when they are recommended and approved by the Independent Review Committee (IRC) and the Chief Advisor of the Foundation. Conditional research grants are expensed by the Foundation as the researchers substantially meet the terms and conditions of the grant during the grant period.

***Revenue Recognition***

The Foundation recognizes contributions and grant income in the year in which the contribution or grant is made. Conditional promises to give are recognized in the period in which the condition is met. Contributions and grants are recorded either as without donor restrictions or with donor restrictions depending on the existence and/or nature of any donor-imposed restrictions. However, it is the policy of the Foundation to recognize restricted contributions and grants that are both received and fully expended during the same fiscal year as net assets without donor restrictions.

Donated assets are recorded as contributions at their fair value on the date of donation.

**TARGET ALS FOUNDATION, INC.**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**Year Ended December 31, 2025**

***Allocation of Expenses***

The Foundation's operating costs have been allocated between research, management and general, and development based on direct identification when possible, and allocation if a single expenditure benefits more than one program or function. Expenditures that require allocation are allocated based on personnel cost. Development expenses consist of fundraising expenses.

***Advertising***

The Foundation charges the costs of advertising to expense as incurred.

***Income Taxes***

The Foundation is exempt from income taxes as a public charity under Section 501(c)(3) of the Internal Revenue Code (IRC). Management believes that the Foundation operates in a manner consistent with its tax-exempt status at both the state and federal levels.

The Foundation annually files IRS Form 990, *Return of Organization Exempt From Income Tax*, reporting various information that the IRS uses to monitor the activities of tax-exempt entities. These tax returns are subject to review by the taxing authorities, generally for a period of three years after they were filed. The Foundation currently has no tax examinations in progress.

***Estimates and Assumptions***

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

***Subsequent Events***

The Foundation has evaluated subsequent events through April 20, 2026, which is the date these financial statements were available to be issued.

**TARGET ALS FOUNDATION, INC.**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**Year Ended December 31, 2025**

**3. Liquidity and Availability**

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, comprise the following at December 31, 2025:

Financial assets:	
Cash	\$ 7,957,798
Investments	83,184,297
Grants receivable	250,000
Pledges receivable, net	<u>45,444,945</u>
Total financial assets	<u>136,837,040</u>
Less: financial assets unavailable for general expenditure:	
Receivables scheduled to be collected in more than one year	35,452,116
Required to satisfy donor purpose restrictions within one year	<u>1,956,596</u>
Total financial assets unavailable for general expenditure	<u>37,408,712</u>
Financial assets available to meet cash needs for general expenditures within one year	<u>\$ 99,428,328</u>

The Foundation has a policy to structure its financial assets to be available as its general expenditures, liabilities and other obligations come due. In addition, as part of its liquidity management, the Foundation manages its liquidity by developing and adopting annual operating budgets that provide sufficient funds for general expenditures in meeting its liabilities and other obligations as they come due. Actual performance is reported and monitored monthly in comparison to budgets. Adjustments are made to the policy as needed to ensure adequate liquidity.

Included within the cash balance above is \$33,103 of grant funding maintained within separately designated accounts at the Foundation’s financial institution. These funds can be utilized to support the Foundation’s mission, as defined in the grant agreement.

**TARGET ALS FOUNDATION, INC.**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**Year Ended December 31, 2025**



**4. Investments**

Investments consisted of the following:

Level 1:	
Money market funds	\$ 22,632,152
Mutual funds – bond funds	44,142,250
Mutual funds – equity funds	<u>16,409,895</u>
Total investments	<u>\$ 83,184,297</u>

**5. Pledges and Grants Receivable**

Pledges receivable consist of unconditional promises to give to support the Foundation’s mission. Grants receivable consist of funding to be received within the terms of executed grant agreements. The present value of pledges receivable has been calculated using interest rates of 3.47% to 4.18%, which approximate the Federal Reserve five-to-ten year Treasury bill rates.

At December 31, 2025, grants receivable consisted of \$250,000 to be collected in 2026.

Pledges receivable are due as follows:

<u>Year Ending</u>	
December 31, 2026	\$ 9,992,829
December 31, 2027	9,645,168
December 31, 2028	6,985,500
December 31, 2029	6,150,000
December 31, 2030	6,018,000
Thereafter	<u>12,804,000</u>
	51,595,497
Less present value component	<u>6,150,552</u>
Pledges receivable, net	<u>\$ 45,444,945</u>

**TARGET ALS FOUNDATION, INC.**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**Year Ended December 31, 2025**



**6. Net Assets**

A summary of net assets is as follows:

Net Assets without Donor Restrictions	<u>\$ 97,650,305</u>
Net Assets with Donor Restrictions	
Subject to expenditure for specified purposes:	
Data Engine	700,000
Expanding Diversity, Representation, and Recruitment	171,498
In Vivo Target Validation Studies	4,330
Research on Related Neurodegenerative Diseases	660,792
U.S. Based Projects	250,000
Springboard Fellowship	44,981
2026 Annual Meeting Support	<u>124,995</u>
	1,956,596
Subject to time restriction	<u>35,452,116</u>
Total net assets with donor restrictions	<u>37,408,712</u>
Total net assets	<u><u>\$ 135,059,017</u></u>

***Data Engine***

Funds from the Secunda Family Foundation are restricted to the creation and maintenance of the Target ALS Data Engine and creation of data sets. The Data Engine hosts comprehensive data collections from Target ALS’s Research Cores, including the Postmortem Tissue Core, Longitudinal Biofluids Core, and Stem Cell Core, facilitating multi-omic analysis (computational scientific analysis in which researchers integrate information about all of the DNA, RNA, or protein in individual cells or samples) to discover ALS biomarkers and therapeutic targets. New data is uploaded to the Data Engine every 4-6 months, ensuring all samples collected from the ALS community through our Cores can have a near-immediate impact on ALS research.

***Expanding Diversity, Representation, and Recruitment***

Funds from the Chan Zuckerberg Initiative are restricted to supporting projects that expand the diversity of patients participating in clinical trials. Local outreach efforts in the Phoenix area will serve as a pilot for expanding such efforts across the country. Additionally, community-based pop-up clinics serve as an easy on-ramp for further trial participation, asking patients for a one-time blood draw. Analyzed data from this collection will be fed into the Data Engine and shared with the scientific community.

**TARGET ALS FOUNDATION, INC.**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**Year Ended December 31, 2025**

***In Vivo Target Validation Studies***

Funds from the ALS Association have been restricted to support In Vivo Target Validation RFAs. The Foundation partners with contract research organizations to enable evaluation of novel therapeutics for target engagement and disease-modifying potential in ALS. Results from these studies have the potential to catapult ALS drug candidates from preclinical to clinical pipelines, accelerating development of novel therapeutics.

***Research on Related Neurodegenerative Disease Areas***

One-third of a \$25,000,000 gift from the Pershing Square Foundation is restricted for projects supporting research in neurodegenerative disease areas related to ALS. The Foundation has awarded grants across its innovation ecosystem for projects related to Frontotemporal Dementia and Alzheimer's Disease.

***U.S. Based Projects***

Funds from the Alper Family Foundation have been restricted to only U.S.-based projects.

***Springboard Fellowship***

A grant from the Hearst Foundation has been restricted to support the Target ALS Springboard Fellowship. This grant is designed to support early-career investigators as they transition from post-docs to independent researchers leading their own labs focusing on ALS research.

***Annual Meeting Support***

Funds received to assist with costs incurred for hosting the Annual Meeting in May 2026.

**7. Commitments and Subsequent Event**

The Foundation enters into commitments annually to award scientific research grants. All research distribution-making decisions are made by the IRC and are reviewed by the Conflict-of-Interest Committee to ensure the IRC has no stake in the projects selected. Subject to the annual review and reapproval process, these distributions generally cover a period of one to two years. Research commitments at December 31, 2025 are reported as grants payable in the accompanying statement of financial position. Subsequent to year-end, the Foundation committed to future research distributions in the amount of approximately \$371,400 for the year ending December 31, 2026.

Except as previously provided for by restricted gifts, the Foundation's ability to meet these distribution commitments may be dependent on future contributions to be received.

**TARGET ALS FOUNDATION, INC.**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**Year Ended December 31, 2025**

**8. Retirement Plan**

The Foundation sponsors a defined contribution plan under Internal Revenue Code Section 403(b). The plan covers all employees over 21 years old, excluding temporary employees. In addition, the Foundation elects to make a noncontributory match equal to 5% of total wages. Employer contributions of approximately \$148,100 were made to the plan during the year ended December 31, 2025.

**9. Concentrations of Risks**

Financial instruments that potentially subject the Foundation to concentrations of credit risk consist of cash, grants and pledges receivable and investments.

The Foundation maintains its cash balance in one financial institution. The balance is insured by the Federal Deposit Insurance Corporation up to \$250,000. From time to time, the Foundation's cash balance may exceed this limit. Cash balances in excess of \$250,000 are generally uninsured.

At December 31, 2025, the Foundation's outstanding pledges receivable were due from seventy-six contributors, three of which represent approximately 46% of pledges receivable. Management has performed an analysis of these receivables at year end and does not believe that there is a significant credit risk related to those receivables.

Investment securities are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is possible that changes in values of investment securities could occur in the near term and that such changes could materially affect investment balances and activity included in the financial statements. At year end, management does not believe that significant credit risk exists relative to the investments.

**TARGET ALS FOUNDATION, INC.**  
**PROGRAM ACCOMPLISHMENTS (UNAUDITED)**  
**Year Ended December 31, 2025**

The Foundation continues to break down barriers to ALS research to find effective treatments. Through our comprehensive strategy to fund research through innovative grant programs, enable research through our Research Cores, and conduct research through our ALS Global Research initiative, we are accelerating the discovery and development of drugs and biomarkers for ALS. Select accomplishments during 2025 include the following:

**RESEARCH WE FUND**

Target ALS is the largest and most impactful private funder of ALS research worldwide. Thanks to the generous trust placed in us by our donors, we can direct resources to the most promising ideas and emerging scientific leaders across the globe. Our funded projects have a high success rate, delivering meaningful results to advance ideas from early to late stage research. In 2025, we continued to expand funding opportunities, driving nearly \$12M into innovation across 151 grants in three critical areas:

- Understanding ALS Biology: Advancing insights into the root causes of disease to identify new drug targets.
- Accelerating Drug Discovery: Supporting proof-of-concept studies that pave the way toward clinical trials.
- Developing Biomarkers: Enabling earlier diagnosis, identifying ALS subtypes, and monitoring disease progression with precision

Every grant that Target ALS funds is tied to a deliberate strategy and a long-range vision for the field, ensuring that promising ideas move through the full research pathway: uncovering disease biology, identifying and refining new therapeutic targets or biomarkers, validating them in rigorous models, generating translational data, and preparing the strongest candidates for clinical development. Our funding allocation reflects where the strongest ideas emerge. The distribution of our funding isn't set by quotas or percentages. It's shaped by where the most compelling science is happening. Each year, we invest in the proposals with the clearest biological rationale, the strongest evidence, and the greatest potential to advance the field.

**RESEARCH WE ENABLE**

Target ALS continues to break down barriers to progress by offering no-strings-attached access to critical tools and resources through our Research Cores. These shared resources address longstanding challenges in ALS research that have historically slowed discovery: limited access, high costs, and lack of standardization.

**TARGET ALS FOUNDATION, INC.**  
**PROGRAM ACCOMPLISHMENTS (UNAUDITED)**  
**Year Ended December 31, 2025**

The Research Cores accelerate drug discovery and biomarker development while fostering collaboration across the global ALS community. In 2025, Target ALS invested over \$8M to empower scientists with the materials, data, and infrastructure they need to drive progress from the bench to the clinic. From our Postmortem Tissue Core to the Longitudinal Biofluids Core powered by our Global Natural History Study (GNHS) and open-access Data Engine, Target ALS provides researchers worldwide with state-of-the-art biosamples, datasets, antibodies, and more, with no reachthrough on intellectual property (IP). These tools are available to both academia and industry, ensuring that scientific breakthroughs can move swiftly and collaboratively toward therapies for people living with ALS.

To date, more than 1,750 projects have relied on these resources, spanning basic biology, target validation, biomarker discovery, and therapeutic development. And the momentum is only growing: over 500 researchers have accessed our Data Engine, while global consortia of preeminent scientists are working together with Target ALS funds to share data, replicate findings, and amplify impact.

#### **RESEARCH WE CONDUCT**

ALS is a disease that affects people of every race and ethnicity around the world. However, clinical trials enroll primarily people of white, European descent resulting in a biased, incomplete view of disease biology across the ALS global population. The ALS Global Research Initiative (AGRI) is the only comprehensive, global research effort that brings together two complementary clinical studies designed to uncover the causes of ALS and identify new biomarkers that can diagnose the disease earlier, track its progression, and predict outcomes.

These studies provide researchers unprecedented access to patient data and biosamples worldwide, rapidly accelerating new discoveries and driving progress toward more effective therapies. Ultimately, inclusive research strengthens scientific validity, improves patient outcomes, and helps ensure that breakthroughs benefit everyone, not just a subset of the population.

Throughout the year, we invested over \$1.5M, which fueled AGRI's bold goal: bring the world together to tackle ALS from every angle. Through our Global Natural History Study (GNHS) and CommunityBased Pop-Up Clinics, we're making ALS research more inclusive, more immediate, and more collaborative than ever before.